Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Phase IIA Trial of Encapsulated Rapamycin (eRapa) to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.

Study Overview

• Status: Active, not recruiting
• Conditions: Familial Adenomatous Polyposis
• Intervention / Treatment: Drug: Encapsulated Rapamycin (eRapa)

Detailed Description

Patients with FAP who are undergoing endoscopic surveillance will be given eRapa at one of three escalating doses/ schedules (0.5mg every other day, 0.5mg daily every other week, or 0.5mg daily) for 12 months with the aim of reducing polyp burden. Patients will serve as their own controls. Patients will be assessed with surveillance endoscopy at baseline, 6 months, and 12 months for change in polyp burden. Correlation between immune markers and clinical outcomes will be explored.

This is a Phase IIa trial which will enroll at approximately 6-8 sites within the United States that have specialty expertise in FAP treatment and surveillance. The trial is anticipated to last approximately 24 months for treatment and follow up.

The trial will enroll 30 patients with the genetic or clinical diagnosis of FAP. The clinical diagnosis includes individuals with 100 or more cumulative tubular adenomas throughout the colorectum. Patients must be undergoing surveillance for known FAP and can include those with intact colons as well as those who have undergone surgical therapy. For those patients who have undergone partial or total colectomy, they must have documented residual polyps in their rectum for which they are receiving active surveillance.

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85054
      • Mayo Clinic Arizona
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic
    • Columbus, Ohio, United States, 43210
      • Ohio State University Wexner Medical Center
  • Texas
    • San Antonio, Texas, United States, 78229
      • UT Health San Antonio
  • Utah
    • Salt Lake City, Utah, United States, 84132
      • Huntsman Cancer Institute and University of Utah

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Sign and date an informed consent form.
2. Stated willingness to comply with all study procedures and availability for the duration of the study.
3. Male or female, age at least 18 years at the time of consent.
4. Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC) germline mutation with or without family history, or with greater than a cumulative lifetime history of (>) 100 adenomas in large intestine and a family history of FAP, or FAP phenotype post colectomy for polyposis with a family history of FAP. Minimum number of polyps required for enrollment is 10.
5. Abilitiy to safely undergo endoscopy.
6. Ability to take oral medication and be willing to adhere to the eRapa regimen.
7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of eRapa administration.
8. A woman must agree not to breast feed or donate eggs (ova, oocytes) during the study and for a period of 12 weeks after the last administration of study drug.

Exclusion Criteria:

1. Risk-reduction surgery (colectomy or partial colectomy) within the 12 months prior to screening.
2. Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The use of 81 milligrams (mg) of aspirin a day or 650 mg of aspirin per week is allowed.
3. Treatment with other FAP-directed drug therapy (including NSAID [Non-steroidal anti-inflammatory drug] drugs), unless completes a 4 week washout period prior to enrollment.
4. Duodenum or colon/ rectum with high grade dysplasia or cancer on biopsy at screening.
5. Duodenal or colorectal polyp > 1 centimeter (cm) not excised at the screening evaluation.
6. Pregnancy or breast feeding.
7. Unable to provide consent or anticipated inability to attend appropriate follow-up visits.
8. Serum creatinine or measured/ calculated creatinine clearance (or glomerular filtration rate [GFR]) > 1.5 x ULN OR < 30mL/min for participants with creatine levels > 1.5 x institutional ULN. Bilirubin ≥ 1.5 x ULN unless conjugated bilirubin ≤ ULN; alkaline phosphatase > 5 x ULN; ALT/AST > 2 x ULN.
9. INR or PT or aPTT > 1.5 x institutional ULN unless the patient is receiving anticoagulant therapy as long as the PT or aPTT is within therapeutic range of intended use of anticoagulants.
10. Proteinuria > 1+ on urinalysis or > 1g/24h on 24h urine.
11. History of interstitial lung disease or non-infectious pneumonitis.
12. Immunosuppressed state (e.g., HIV, use of chronic steroids), active, uncontrolled infection.
13. On agents known to alter rapamycin metabolism significantly.
14. Concurrent involvement in other clinical trials specifically evaluating chemoprevention in FAP.
15. Patients with a colonic polyp burden too numerous to count.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1; Cohort 1 will receive 0.5mg of eRapa every other day.	Drug: Encapsulated Rapamycin (eRapa); eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.; Other Names: eRapa; Encapsulated sirolimus
Experimental: Cohort 2; Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.	Drug: Encapsulated Rapamycin (eRapa); eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.; Other Names: eRapa; Encapsulated sirolimus
Experimental: Cohort 3; Cohort 3 will receive 0.5 mg of eRapa daily.	Drug: Encapsulated Rapamycin (eRapa); eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.; Other Names: eRapa; Encapsulated sirolimus

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency and severity of adverse events associated with low dose eRapa in FAP patients	Safety and tolerability of eRapa as determined by graded toxicity assessed throughout the trial per CTCAE v5.0.	All adverse events with start dates occurring any time after informed consent is obtained until 7 days (for non-serious adverse events) or 30 days (for serious adverse events) after the last day of study participation will be recorded.
Determine the Recommended Phase 2 Dose (RP2D)	The Recommended Phase 2 Dose (RP2D) will be determined by examining and analyzing safety/ adverse events as reflected by Outcome 1, dose delays, dose reductions, withdrawal of treatment secondary to low-grade toxicities, and serum pharmacokinetic monitoring.	After informed consent is obtained up to 30 days after the last day of study participation.
Efficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.	Percentage change from baseline in colorectal polyp burden as measure by endoscopy at 6 months.	Time for each patient is baseline to 6 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical effect of eRapa on polyp burden.	Percentage change from baseline in colorectal polyp burden at 12 months.	Following patients out to 12 months.
Clinical effect of eRapa on International Society for Gastrointestinal Hereditary Tumors Stage.	Change from baseline in International Society for Gastrointestinal Hereditary Tumors Stage at 6 and 12 months.	Following patients out to 6 and 12 months.
Clinical effect of eRapa on Spigelman Stage Score.	Change from baseline in Spigelman Stage Score at 6 and 12 months in patients with polyps at baseline on EGD. The Spigelman scoring system assigns points (0, 1, 2, or 3) based on number of adenomas, size (mm), histology, and dysplasia. The scoring ranges from 0 to 12 points. A higher score is a worse outcome.	Following patients out to 6 and 12 months.
Clinical effect of eRapa on duodenal polyp number and burden.	Percentage change from baseline in the duodenal polyp number and burden at 6 and 12 months in patients with polyps at baseline on EGD.	Following patients out to 6 and 12 months.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Explore correlation between immune markers influenced by mTOR inhibition and clinical outcomes	Immunologic response will be measured and will include overall assessment of T cell phenotype and function.	Following patients out to 12 months.

Collaborators and Investigators

• Sponsor: Rapamycin Holdings, Inc. dba Emtora Biosciences
• Collaborators: LumaBridge
• Investigators: Study Director: George E Peoples, MD, Sponsor CMO

Study record dates

Study Major Dates

• Study Start (Actual): January 18, 2021
• Primary Completion (Anticipated): February 1, 2023
• Study Completion (Anticipated): February 1, 2023

Study Registration Dates

• First Submitted: January 12, 2020
• First Submitted That Met QC Criteria: January 14, 2020
• First Posted (Actual): January 18, 2020

Study Record Updates

• Last Update Posted (Actual): October 5, 2022
• Last Update Submitted That Met QC Criteria: October 3, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Genetic Diseases, Inborn; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Neoplastic Syndromes, Hereditary; Adenomatous Polyps; Adenoma; Intestinal Polyposis; Nasopharyngeal Neoplasms; Colorectal Neoplasms; Adenomatous Polyposis Coli; Physiological Effects of Drugs; Anti-Infective Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Sirolimus
• Other Study ID Numbers: EMT-FAP-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No